PharmaVentures

Listen as Adrian Dawkes talks to Kurt Herpel, CEO and Klaus Kratochwill, CSO of Delta 4, an Austrian /Swiss based AI tech company. Hear how their AI journey began more than 20 years ago and how the company developed into a key player in AI drug discovery. Hear how their clients are already benefiting from AI. You will hear their insights into; • Where AI is benefiting drug discov

Listen as Soren Demin draws on his 20 years of M&A experience to provide insight into the current Pharma/Biotech M&A landscape. Key topics include; Is the M&A landscape recovering and will we see record activity again? How has the big pharma model changed and what is the impact on deal making? What is the direction of travel for deal volumes and values? How do biotechs

Listen as Andreas Katsiamides talks with Adrian Dawkes about the future of diagnostics and the impact on deals. They discuss: Technological advances in diagnostics, such as artificial intelligence (AI), next-generation sequencing (NGS) and polymerase chain reaction (PCR) testing Its application to specific medical models and therapy areas – including personalised medicine, oncol

Listen as Colin McCall, Partner - Life Sciences and Deep Tech at Taylor Wessing, and Oliver Pumfrey, Managing Director at FTI Consulting, talk with Adrian Dawkes about law and tax during the licensing and M&A deal making process. They discuss a range of topics where different advisors use their expertise to help you achieve the best deal and avoid pitfalls in the future: The

Once you have identified an asset you want to acquire or partner, what happens next? In this podcast, Ralph Hughes takes the listener through the process of commercial due diligence and evaluation, including the key stakeholders and insights needed to understand whether the asset is going to achieve strong performance in the marketplace. Ralph talks to Adrian Dawkes about the d

Listen as Andrew Guise gives key insight into the deal making landscape - asset value, accessing the market, positioning and the actual deal process in the current economic climate - from the unique position standing astride both the financial world and the technical world translating science into value. About the Interviewee: Andrew Guise is a Managing Director at PharmaVentures

Listen as Jansen Jacob, Frank Dollard and Steve Garland discuss the ways in which pharma and biotech companies are getting control back over their supply chain and the opportunities they are seeing from best practice; how the importance of quality and efficiency, including moves towards new low-cost regions in the West, are reducing risk for manufacturers whilst governments are try

Listen as Fintan Walton, PharmaVentures’ CEO and Founder, discusses the 4 common mistakes being made in partnering and how to avoid them. Fintan provides insight into how to achieve successful deal outcomes by avoiding risks along the clinical, commercial and regulatory pathway, and what fact-based data you need to get your drug to market with the right partner at the right pri

Listen as Ralph Hughes, PharmaVentures’ Pricing and Market Access expert, talks with Adrian Dawkes about how you can reduce the risk when you want to get your asset onto the market and get ahead of the competition. Understanding incentives, perspectives and funding flows can lead to better pricing and development strategies. Understanding payer perspectives can help you define

Listen as Ben Jacoby, Regulatory Expert, talks with Adrian Dawkes about the transition to the new regulations in Europe and UK.